Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Gastrointestinal 203 Thoracic 79 Breast 78 CNS 73 Head & Neck 62 Sarcoma 44 Gynecologic 33 Genitourinary 33 Dermatologic 25 Tumor-Agnostic 8 Endocrine 6 Other solid neoplasm 5 Other 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41 Everolimus 38 Magnetic Resonance Spectroscopy 18 Temozolomide 17 lanreotide 16 gallium Ga 68 dotatate 15 Octreotide 14 pembrolizumab 13 Nivolumab 13 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 9 pasireotide 9 Sunitinib 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Lutetium-177 8 Carboplatin 8 amino-acid, glucose, and electrolyte solution 6 Ipilimumab 6 Ga(III)-DOTATOC 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 copper dotatate CU-64 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Surgical Procedures, Operative × NET × Clear all

NCT03012789 2024-04-30

NETest_Sx

Wren Laboratories LLC

Phase NA Active not recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡